On Tuesday, PepGen Inc. PEPG introduced its voluntary choice to quickly pause the Section 2 CONNECT2-EDO51 research of PGN-EDO51 in sufferers with Duchenne muscular dystrophy (DMD) till the corporate can evaluation outcomes from the ten mg/kg cohort.
The primary two cohorts of the CONNECT1 research are absolutely enrolled and knowledge from the ten mg/kg cohort are anticipated through the third quarter of 2025. No new questions of safety associated to PGN-EDO51 have been noticed for the reason that firm’s final security replace as of January 23, 2025.
Additionally Learn: Capricor Therapeutics Cell Remedy Goes Below Precedence FDA Evaluate For Duchenne Related-Coronary heart Situation
“With our 10 mg/kg cohort of CONNECT1 research absolutely enrolled and knowledge anticipated later this 12 months, we determined to pause CONNECT2 till we’re capable of evaluation outcomes from the ten mg/kg cohort in sufferers with DMD. This may enable us to collect further security knowledge, assess the affect of this dose of PGN-EDO51 on dystrophin ranges, and probably enhance the design of CONNECT2,” mentioned James McArthur, president and CEO of PepGen.
“This choice permits us to focus assets on finishing CONNECT1, in addition to quickly advancing our FREEDOM research in myotonic dystrophy sort 1 with PGN-EDODM1, by which we lately reported encouraging preliminary scientific knowledge from the Section 1 FREEDOM-DM1 research,” McArthur added.
In February, PepGen introduced early knowledge from its FREEDOM-DM1 trial for myotonic dystrophy.
The research confirmed vital dose-dependent splicing correction, with imply corrections of 12.3% at 5 mg/kg and 29.1% at 10 mg/kg at 28 days post-dosing.
Worth Motion: PEPG inventory is down 21% at $2.22 on the final verify Tuesday.
Learn Subsequent:
Picture: Gorodenkoff/Shutterstock.com
Market Information and Information dropped at you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
